Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer
Yong-Li Gu1, Zeng-Xian Sun1, Ying Sun1, Xin Guan2, Dao-Li Jiang3
1 Department of Pharmacy, The First People’s Hospital of Lianyungang, Lianyungang, 2 School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, and 3 Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
| Warenkorb Übersicht | ||||
| Typ | Anz | Rabatt | MwSt | Preis |
| Der Warenkorb ist leer | ||||
| Ihr Warenkorb | ||||